Patrick Hwu, MD, Chair of the Department of Melanoma Medical Oncology M. D. Anderson Cancer Center: Therapeutic Vaccine Improves Response Rate and Extends Progression-Free Survival in Patients with Metastatic Melanoma: Preliminary findings from a phase III, multicenter trial show that adding a novel cancer vaccine – called gp100:209-217(210M) peptide – to standard therapy doubles response rates and extends progression-free survival in patients with metastatic melanoma, without causing significant side effects.